Craif Raises $34M for AI Urine Cancer Detection Technology

Craif Inc., a pioneer in bio-AI for early disease detection, has successfully closed a $34 million Series D funding round. The investment was co-led by Granite-Integral, a strategic alliance between Granite Asia and Integral Corporation, alongside Japan's diagnostics leader, Tauns Co., Ltd. This significant capital infusion propels Craif's mission to bring its innovative urine-based cancer screening technology to the U.S. market.

The financing, which also saw participation from Unreasonable and existing backer X&KSK, along with other international investors, brings Craif's total funding to approximately $90 million since its inception in 2018. The Series D round comprised roughly $30.7 million in equity and $3.3 million in debt, underscoring a robust financial structure for the company's ambitious expansion plans.

Proceeds from this round are earmarked for critical U.S. research and development initiatives, including the establishment of a prospective clinical study focused on pancreatic cancer. This study aims to build the necessary evidence base for a reimbursement-driven launch of Craif's non-invasive diagnostic test in the United States. Furthermore, the funds will support Craif's ongoing Japanese regulatory submission for a software-based medical device program targeting pancreatic cancer diagnosis.

Craif's proprietary platform analyzes microRNA biomarkers in urine, leveraging artificial intelligence to identify early signs of cancer. The technology has already demonstrated significant traction in Japan, where its flagship test, miSignal, is available at over 2,500 medical facilities and 4,500 pharmacies, having completed more than 100,000 tests. The company's scientific foundation is supported by over 80 peer-reviewed publications and presentations, including key findings on early pancreatic cancer detection.

The investment by Granite-Integral highlights confidence in Craif's unique technological capabilities, its validated commercial strategy in Japan, and the substantial unmet need for accessible cancer screening in the U.S. Current screening methods for high-risk individuals, such as MRI and endoscopic ultrasound, are often invasive and difficult to access, creating a clear market opportunity for Craif's less intrusive approach.

To drive its U.S. clinical strategy, Craif has appointed Dr. Nicholas Bevins as its new Chief Medical Officer. Dr. Bevins, a board-certified clinical pathologist with extensive experience in diagnostics and biotechnology leadership, will oversee the clinical development roadmap, crucial for navigating U.S. regulatory and reimbursement pathways. His expertise is vital as Craif scales its San Diego laboratory operations and advances partnerships with 30 medical institutions across 15 states.

The strategic importance of the U.S. market is further emphasized by the relocation of Craif's CEO, Ryuichi Onose, to San Diego, and the recent appointment of Takeo Mukai, formerly of Medtronic, as Chief Financial Officer. This Series D funding represents a pivotal moment for Craif, positioning it to address a critical gap in early cancer detection and potentially redefine diagnostic standards globally.